Allergy Therapeutics opened its new production facility at Worthing, U.K. The new building houses a production line for the company’s Pollinex® Quattro allergy vaccine, which is currently supplied on a named patient basis in Europe.
The company reports that Pollinex Quattro is also in Phase III development in the first ever Phase III global allergy vaccine trial.
The new plant has been named The Noon Building while Allergy Therapeutics’ existing building has been renamed The Freeman Building. The namings were in honor of Leonard Noon, M.D., and John Freeman, M.D., who, while working at St. Mary’s Hospital in London, were the first to use allergy vaccines (published June 1911 in The Lancet).
In acknowledgment of the pioneering nature of this work Allergy Therapeutics will be making a Research Grant to St. Mary’s Hospital.